Facial Plast Surg 2019; 35(03): 230-238
DOI: 10.1055/s-0039-1688844
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neurotoxins

1   Department of Otolaryngology, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York
,
David A. Sherris
1   Department of Otolaryngology, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York
› Institutsangaben
Funding The authors have no financial disclosures.
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. Juni 2019 (online)

Abstract

Botulinum toxin is integral to the practice of facial plastic surgery. Since it was approved by the U.S. Food and Drug Administration for the temporary improvement of glabellar rhytids in 2002, botulinum toxin has achieved a growing number of off-label clinical applications. These include the management of facial rhytids, brow ptosis, excessive gingival display, masseteric hypertrophy, platysmal banding, facial nerve paralysis, hypertrophic scars, and keloids. Many forms of botulinum toxin have been developed, and their safety and efficacy have been thoroughly established. This article will review the aesthetic and functional uses of botulinum toxin as it relates to the field of facial plastic and reconstructive surgery. In addition, the authors will discuss the suggested quantity of units per injection site based on onabotulinumtoxinA.

Supplementary Material

 
  • References

  • 1 Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12 (12) 924-927
  • 2 Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 1989; 84 (02) 353-355
  • 3 Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18 (01) 17-21
  • 4 American Society of Plastic Surgeons. 2017 Plastic Surgery Statistics Report. Available at: https://www.plasticsurgery.org/documents/News/Statistics/2017/plastic-surgery-statistics-full-report-2017.pdf . Accessed October 30, 2018
  • 5 Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000; 43 (2 Pt 1): 249-259
  • 6 Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324 (17) 1186-1194
  • 7 Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 1989; 92 (2-3): 181-192
  • 8 Sezgin B, Ozel B, Bulam H, Guney K, Tuncer S, Cenetoglu S. The effect of microneedle thickness on pain during minimally invasive facial procedures: a clinical study. Aesthet Surg J 2014; 34 (05) 757-765
  • 9 Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103 (02) 701-713
  • 10 Huang W, Rogachefsky AS, Foster JA. Browlift with botulinum toxin. Dermatol Surg 2000; 26 (01) 55-60
  • 11 Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N. ; Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112 (04) 1089-1098
  • 12 Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Caird D. ; German-Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007; 33 (1 Spec No.): S18-S25
  • 13 Carruthers A, Carruthers J. Eyebrow height after botulinum toxin type A to the glabella. Dermatol Surg 2007; 33 (1 Spec No.): S26-S31
  • 14 Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg 2003; 29 (05) 468-476
  • 15 Suber JS, Dinh TP, Prince MD, Smith PD. OnabotulinumtoxinA for the treatment of a “gummy smile.”. Aesthet Surg J 2014; 34 (03) 432-437
  • 16 Cohen JL, Dayan SH, Cox SE, Yalamanchili R, Tardie G. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatol Surg 2012; 38 (09) 1497-1505
  • 17 Choi YJ, Kim JS, Gil YC. , et al. Anatomical considerations regarding the location and boundary of the depressor anguli oris muscle with reference to botulinum toxin injection. Plast Reconstr Surg 2014; 134 (05) 917-921
  • 18 Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg 2010; 125 (06) 1693-1705
  • 19 Lee SH, Wee SH, Kim HJ. , et al. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients. J Dermatolog Treat 2013; 24 (02) 133-136
  • 20 Kane MA. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg 1999; 103 (02) 656-663 , discussion 664–665
  • 21 Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 1999; 103 (02) 645-652 , discussion 653–655
  • 22 Levy PM. The ‘Nefertiti lift’: a new technique for specific re-contouring of the jawline. J Cosmet Laser Ther 2007; 9 (04) 249-252
  • 23 Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol 2013; 34 (02) 319-324
  • 24 Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 2000; 105 (06) 1948-1953 , discussion 1954–1955
  • 25 Gassner HG, Brissett AE, Otley CC. , et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006; 81 (08) 1023-1028
  • 26 Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen 2014; 22 (05) 605-612
  • 27 Hu L, Zou Y, Chang SJ. , et al. Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial. Plast Reconstr Surg 2018; 141 (03) 646-650
  • 28 Ziade M, Domergue S, Batifol D. , et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg 2013; 66 (02) 209-214
  • 29 Tollefson TT, Senders CM, Sykes JM, Byorth PJ. Botulinum toxin to improve results in cleft lip repair. Arch Facial Plast Surg 2006; 8 (03) 221-222
  • 30 Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg 2014; 134 (03) 511-516
  • 31 Robinson AJ, Khadim MF, Khan K. Keloid scars and treatment with botulinum toxin type A: the Belfast experience. J Plast Reconstr Aesthet Surg 2013; 66 (03) 439-440
  • 32 Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg 2009; 124 (05) 275e-277e
  • 33 Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol 2012; 25 (06) 313-318
  • 34 Haubner F, Leyh M, Ohmann E, Sadick H, Gassner HG. Effects of botulinum toxin A on patient-specific keloid fibroblasts in vitro. Laryngoscope 2014; 124 (06) 1344-1351
  • 35 Jeong HS, Lee BH, Sung HM. , et al. Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg 2015; 136 (02) 171e-178e
  • 36 Xiao Z, Zhang M, Liu Y, Ren L. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthetic Plast Surg 2011; 35 (05) 802-807
  • 37 Goodman GJ. The use of botulinum toxin as primary or adjunctive treatment for post acne and traumatic scarring. J Cutan Aesthet Surg 2010; 3 (02) 90-92
  • 38 Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 2006; 117 (06) 1758-1766 , discussion 1767–1768
  • 39 Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg 2009; 33 (03) 409-412
  • 40 Borodic G. Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthal Plast Reconstr Surg 2006; 22 (03) 239-240
  • 41 Torres S, Hamilton M, Sanches E, Starovatova P, Gubanova E, Reshetnikova T. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol 2013; 7: 11-17
  • 42 Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003; 250 (08) 967-969
  • 43 Durand PD, Couto RA, Isakov R. , et al. Botulinum toxin and muscle atrophy: a wanted or unwanted effect. Aesthet Surg J 2016; 36 (04) 482-487
  • 44 Guyuron B, Rose K, Kriegler JS, Tucker T. Hourglass deformity after botulinum toxin type A injection. Headache 2004; 44 (03) 262-264
  • 45 Fortuna R, Vaz MA, Youssef AR, Longino D, Herzog W. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox). J Biomech 2011; 44 (01) 39-44